Satellos Bioscience MSLE 深 滬
等待開盤 10-08 09:30:00 美东时间
7.63
+0.090
+1.19%
華盛通- 最 高8.35
- 今 開7.70
- 成交量 4.77万股
- 最 低 7.44
- 昨 收 7.54
- 總市值 1.62亿
- 52周最高 13.3949
- 市盈率 靜 --
- 換手率 0.22%
- 52周最低 5.44
- 委 比 50.00%
- 總股本 2121.64万
- 歷史最高 13.3949
- 量 比 0.88
- 振 幅 12.07%
- 歷史最低 5.44
- 每 手 1
- 風險率 1.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,747,245, entitled "AP2 a...
10-05 19:10
Satellos Granted Composition of Matter Patent for Forazapadin
Satellos Bioscience Inc. has been granted U.S. Patent No. 12,747,245, providing composition of matter protection for forazapadin, its lead drug candidate, through Sept. 6, 2044. The patent covers forazapadin and a broader class of AAK1 inhibitors, supporting Satellos' long-term development and commercialization strategy. Forazapadin, an oral, small molecule drug, targets AAK1 to help restore muscle repair and regeneration, addressing degenerative...
10-05 11:00
FDA Clears Satellos Bioscience’s IND Application For Forazapadin For Treatment Of Facioscapulohumeral Muscular Dystrophy
FDA clearance expands development of forazapadin into a second degenerative muscle disease with significant unmet medical need FSHD Canada Foundation to provide up to US$5 million in non-dilutive financing toward the clinical development of forazapadin in FSHD Phase 2 study in FSHD expected to begin...
09-24 19:01
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
Satellos Bioscience announced FDA clearance for its IND application to develop forazapadin for facioscapulohumeral muscular dystrophy (FSHD). The company plans to initiate a Phase 2 clinical trial in Q4 2026. FSHD Canada Foundation will provide up to $5 million in non-dilutive financing. FSHD affects ~800,000 globally, with no approved therapies. Forazapadin is also being studied for Duchenne muscular dystrophy, showing promising early results.
09-24 11:00
Satellos to Present at the 31st Annual Congress of the World Muscle Society
Satellos Bioscience Inc. announced four poster presentations at the 31st Annual Congress of the World Muscle Society (WMS) in Hiroshima, Japan. The posters highlight clinical and preclinical studies of Forazapadin (SAT-3247), a novel AAK1 inhibitor targeting Duchenne muscular dystrophy (DMD) and other degenerative muscle diseases. Presentations include Phase 2a and long-term safety studies in DMD patients, preclinical to human translation of musc...
09-15 11:00
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
Satellos Bioscience has named its drug candidate SAT-3247 as "forazapadin," a small molecule designed to restore muscle regeneration in degenerative diseases like Duchenne muscular dystrophy (DMD). The drug targets AAK1 to support muscle repair. Currently in Phase 2 studies for DMD, Satellos plans a Phase 2 trial for facioscapulohumeral muscular dystrophy (FSHD) by year-end. The company emphasizes the drug's potential as a disease-modifying treat...
09-09 11:00
Satellos to Participate in Upcoming Investor Conferences
Satellos Bioscience Inc. announced its participation in two investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and the H.C. Wainwright 28th Annual Global Investment Conference on September 16. The company will also host one-on-one investor meetings during both events. Satellos is developing SAT-3247, an oral AAK1 inhibitor targeting Duchenne muscular dystrophy (DMD) and other degenerative muscle disease...
09-01 11:00
HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $18 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Satellos Bioscience (NASDAQ:MSLE) with a Buy and maintains $18 price target.
08-17 18:34
Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate
Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 43.59 percent decrease over losses of $(0.39) per share from the same period last year.
08-14 05:04
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
Satellos Bioscience reported positive interim data from the TRAILHEAD Phase 2 adult DMD study, showing reduced muscle fat fraction and increased effort, suggesting muscle regeneration. The company also noted favorable safety and tolerability, stable strength, and improved quality of life. SAT-3247 received FDA Fast Track Designation for DMD. The BASECAMP pediatric study is advancing, with plans to report data in Q4 2026. The company has a strong ...
08-13 21:02
